What does accrued research and development expenses mean?

This represents the total amount of research and development costs incurred by the company for which payment has not yet been made. It reflects ongoing investment in technology infrastructure and tokenization protocols that have been recognized as expenses but remain as liabilities on the balance sheet.

BioSig Technologies, Inc. STEX Accrued Research And Development Expenses

Accrued Research And Development Expenses at other companies

Immix Biopharma, Inc.IMMX

$4.4M+73.5%

Oruka Therapeutics, Inc.ORKA

$6.81M+56.1%

electroCore, Inc.ECOR

$655K0.0%

Polaryx Therapeutics, Inc. PLYX

$86K—

Rigel PharmaceuticalsRIGL

$5.74M+23.5%

Ironwood PharmaceuticalsIRWD

$2.04M-63.7%

Other financials

Income statement

See full

Revenue$13.0K+8.3%

Gross profit$12.0K-88.9%

Operating income-$35.7M-1,098%

Net income-$46.7M-1,560%

EPS (diluted)-$0.27-92.9%

Balance sheet

See full

Cash & equivalents$6.9M+84.0%

Total debt$15.0K-94.7%

Total equity$159.0M+6,003%

Total assets$173.3M+3,823%

Cash flow

See full

Operating cash flow-$10.2M-813%

CapEx$4.0K-93.1%

Free cash flow-$2.9M+29.4%

Valuation

See full

Market cap$88.66M-61.8%

P/S2,216.6×-5,967×

Profitability

See full

Gross margin80.1%+25.2pp

Operating margin-32,155%-14,261pp

Net margin-25,825%-11,789pp

FCF margin-97,216.7%-106,293pp

Returns & leverage

See full

Return on equity-627.1%—

Debt / equity0×—

Current ratio13.9×+11.5×

Where this comes from

Reported directly by BioSig Technologies, Inc. in its filing.

Tagged under the XBRL concept STEX:AccruedResearchAndDevelopmentExpenses.

The official record: BioSig Technologies, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioSig Technologies, Inc.'s accrued research and development expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioSig Technologies, Inc.'s accrued research and development expenses?: BioSig Technologies, Inc. (STEX) reported accrued research and development expenses of $167K in Q1 2026.
What does accrued research and development expenses mean?: This represents the total amount of research and development costs incurred by the company for which payment has not yet been made. It reflects ongoing investment in technology infrastructure and tokenization protocols that have been recognized as expenses but remain as liabilities on the balance sheet.